IceCure Medical (ICCM) Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $2.1 million for the first nine months of 2025, down from $2.4 million in the same period in 2024. The decline was attributed to reduced sales in Japan and other territories, partially offset by increased sales in Latin America.

Gross Profit: $626,000, up from $134,000 year-over-year, resulting in a gross margin of 30% compared to 43% in 2024.

Operating Expenses: Decreased to $11.5 million from $12.2 million, reflecting cost optimization efforts.

Net Loss: $10.8 million, or $0.18 per share, compared to a net loss of $10 million, or $0.22 per share, in the prior year.

Cash Position: $10 million in cash and equivalents as of September 30, 2025, up from $7.6 million at the end of 2024, bolstered by a successful rights offering that raised $10 million.

2Strategic Updates and Business Highlights

FDA Authorization: Significant milestone achieved with FDA marketing authorization for the ProSense system to treat low-risk breast cancer in women aged 70 and older, expanding the addressable market to approximately 200,000 patients annually.

Commercial Expansion: Over 20 commercial sites using ProSense prior to FDA approval, with plans to increase installations and utilization. A post-market study is planned with 30 clinical sites.

International Interest: Growing global interest in ProSense, with recent approvals in Switzerland and ongoing discussions with a Brazilian medical delegation.

Innovation: Continued progress on new product development and intellectual property, including a recent patent allowance in the U.S. and Japan.

3Forward Guidance and Outlook

The company anticipates fluctuations in revenue as commercial activities ramp up following FDA clearance.

Expected increase in CPT reimbursement rates in January 2026, which should enhance patient access.

Plans to submit a regulatory application in Japan in the first half of 2026, expanding market access.

4Bad News, Challenges, or Points of Concern

Revenue Decline: Year-over-year revenue decline raises concerns about market traction and sales execution in certain regions.

Gross Margin Pressure: A decrease in gross margin from the previous year may indicate challenges in cost management or pricing pressures.

Regulatory Risks: Awaiting final approval for the post-market study protocol from the FDA, which could delay patient recruitment and further commercialization efforts.

5Notable Q&A Insights

Management confirmed ongoing communication with the FDA regarding the post-market study, with expectations for final approval by early 2026.

Clarification on the expanded patient population eligible for cryoablation, including an additional 88,000 patients who are not surgical candidates and 63,000 patients with benign tumors, enhancing the addressable market significantly.

Management expressed confidence in the growth trajectory post-FDA authorization, emphasizing the strategic importance of their commercialization efforts in the U.S. and globally. This summary encapsulates the key elements from the earnings call, providing a balanced view of IceCure Medical's current performance and future outlook.